233 related articles for article (PubMed ID: 31871950)
1. Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus.
Funamoto M; Shimizu K; Sunagawa Y; Katanasaka Y; Miyazaki Y; Kakeya H; Yamakage H; Satoh-Asahara N; Wada H; Hasegawa K; Morimoto T
J Diabetes Res; 2019; 2019():8208237. PubMed ID: 31871950
[TBL] [Abstract][Full Text] [Related]
2. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
Funamoto M; Sunagawa Y; Katanasaka Y; Miyazaki Y; Imaizumi A; Kakeya H; Yamakage H; Satoh-Asahara N; Komiyama M; Wada H; Hasegawa K; Morimoto T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2029-34. PubMed ID: 27616885
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.
Grant SJ; Chang DH; Liu J; Wong V; Kiat H; Bensoussan A
BMC Complement Altern Med; 2013 May; 13():104. PubMed ID: 23672597
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
5. Cinnamomum zeylanicum (Ceylon cinnamon) as a potential pharmaceutical agent for type-2 diabetes mellitus: study protocol for a randomized controlled trial.
Ranasinghe P; Galappaththy P; Constantine GR; Jayawardena R; Weeratunga HD; Premakumara S; Katulanda P
Trials; 2017 Sep; 18(1):446. PubMed ID: 28962661
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
8. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM.
Reaven PD; Herold DA; Barnett J; Edelman S
Diabetes Care; 1995 Jun; 18(6):807-16. PubMed ID: 7555507
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T
J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058
[TBL] [Abstract][Full Text] [Related]
10. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance.
Tsunoda T; Nozue T; Yamada M; Mizuguchi I; Sasaki M; Michishita I
Diabetes Res Clin Pract; 2013 Apr; 100(1):46-52. PubMed ID: 23369229
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
[TBL] [Abstract][Full Text] [Related]
12. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Adibian M; Hodaei H; Nikpayam O; Sohrab G; Hekmatdoost A; Hedayati M
Phytother Res; 2019 May; 33(5):1374-1383. PubMed ID: 30864188
[TBL] [Abstract][Full Text] [Related]
13. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
14. Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.
Sasaki M; Imaeda K; Okayama N; Mizuno T; Kataoka H; Kamiya T; Kubota E; Ogasawara N; Funaki Y; Mizuno M; Iida A; Goto C; Koikeda S; Kasugai K; Joh T
Diabetes Obes Metab; 2012 Apr; 14(4):379-82. PubMed ID: 22098444
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
16. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.
Arnetz L; Hage C; Ekberg NR; Alvarsson M; Brismar K; Norhammar A; Mellbin L
Growth Horm IGF Res; 2015 Dec; 25(6):298-303. PubMed ID: 26283275
[TBL] [Abstract][Full Text] [Related]
17. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.
Moreira-Lucas TS; Duncan AM; Rabasa-Lhoret R; Vieth R; Gibbs AL; Badawi A; Wolever TM
Diabetes Obes Metab; 2017 Jan; 19(1):133-141. PubMed ID: 27717236
[TBL] [Abstract][Full Text] [Related]
18. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study.
Nakagawa Y; Mukai S; Yamada S; Matsuoka M; Tarumi E; Hashimoto T; Tamura C; Imaizumi A; Nishihira J; Nakamura T
J Orthop Sci; 2014 Nov; 19(6):933-9. PubMed ID: 25308211
[TBL] [Abstract][Full Text] [Related]
19. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
[TBL] [Abstract][Full Text] [Related]
20. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance.
Kajiyama S; Hasegawa G; Asano M; Hosoda H; Fukui M; Nakamura N; Kitawaki J; Imai S; Nakano K; Ohta M; Adachi T; Obayashi H; Yoshikawa T
Nutr Res; 2008 Mar; 28(3):137-43. PubMed ID: 19083400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
